Synthesis of anti-rheumatic agent epoxyquinomicin B
N Matsumoto1, H Iinuma, T Sawa
1Institute of Microbial Chemistry, Tokyo, Japan.
Bioorganic & Medicinal Chemistry Letters
|January 5, 1999
Summary
Researchers synthesized the anti-rheumatic agent (+/-)-epoxyquinomicin B. This compound was prepared in eight steps from readily available starting materials, utilizing Fremy
Area of Science:
- Organic Chemistry
- Medicinal Chemistry
- Synthetic Chemistry
Background:
- Rheumatic diseases are a significant cause of disability worldwide.
- Epoxyquinomicin B is a potential anti-rheumatic agent.
- Efficient synthesis of complex organic molecules is crucial for drug discovery.
Purpose of the Study:
- To develop a synthetic route for (+/-)-epoxyquinomicin B.
- To achieve a viable overall yield for the target compound.
- To explore key chemical transformations for synthesizing anti-rheumatic agents.
Main Methods:
- Multi-step organic synthesis starting from 3-hydroxy-4-nitrobenzaldehyde.
- Selective phenol oxidation using Fremy's salt as a key step.
- Purification and characterization of the intermediate quinone and final product.
Main Results:
- The synthesis of (+/-)-epoxyquinomicin B was achieved in eight steps.
- An overall yield of 22% was obtained for the target compound.
- The key step involved selective phenol oxidation to form the intermediate quinone.
Conclusions:
- A practical synthetic pathway for (+/-)-epoxyquinomicin B has been established.
- The synthesis demonstrates the utility of Fremy's salt in selective oxidation reactions.
- This work provides a foundation for further investigation of epoxyquinomicin B as an anti-rheumatic agent.
Related Concept Videos
Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...


